- Company
- Sales of K-anticancer drugs Leclaz and Rolontis rise in KOR
- by Chon, Seung-Hyun Nov 24, 2023 05:37am
- New anticancer drugs developed by domestic companies are gradually increasing their influence in their home market. Sales of Yuhan Corp’s lung cancer treatment Leclaza are expected to exceed KRW 20 billion this year. Also, cumulative sales of Hanmi Pharmaceutical's neutropenia treatment Rolontis have exceeded KRW 10 billion just 2 two into its
- Company
- MSD vaccines will be sold by Boryung·Kwangdong
- by Kim, Jin-Gu Nov 24, 2023 05:37am
- The domestic sales rights for 8 types of MSD vaccines have changed hands recently. Although HK Inno.N was in charge of joint sales for MSD vaccines in Korea, the vaccines will be separately sold by Boryung Biopharma and Kwangdong Pharmaceutical each. After signing a copromotion agreement with MSD for its vaccines at the end of 2021, HK
- Company
- Reimb for 7 of 13 Keytruda indications to be rediscussed
- by Eo, Yun-Ho Nov 24, 2023 05:37am
- Although it was well expected, the road to reimbursement extension for Keytruda is not going so smoothly. The company had applied to extend reimbursement for the drug to 13 additional indications in bulk earlier this year. According to industry sources, 4 indications of MSD Korea’s PD-1 inhibitor Keytruda (pembrolizumab) for Triple-Neg
- Company
- Shingrix lead mkt again…shakes shingles vaccine mkt
- by Chon, Seung-Hyun Nov 23, 2023 05:37am
- The annual KRW 40 billion shingles vaccine market has shown rapid changes. GlaxoSmithKline's (GSK) new shingles vaccine 'Shingrix' took an unrivaled lead in the Korean market. Shingrix’s market share exceeded 50% this quarter powered by its strong preventive effect despite its high price. According to the market research institution IQVIA on
- Company
- SK Bioscience & Hilleman Laboratories develop Ebola vaccine
- by Kim, Jin-Gu Nov 23, 2023 05:37am
- SK Bioscience announced on the 22nd that it signed a memorandum of understanding (MOU) with Hilleman Laboratories, an international non-profit research institute, for the joint development of a second-generation Zaire Ebola virus vaccine. Hilleman Laboratories was established in 2009 as an equal joint venture between MSD and Wellcome Tr
- Company
- Leukemia drug Xospata’s reimb limit may be resolved
- by Eo, Yun-Ho Nov 23, 2023 05:37am
- Astellas Korea is working to resolve the issue of the reimbursed number of cycles approved for its acute myeloid leukemia treatment ‘Xospata.’ Dailpharm’s coverage showed that the agenda on expanding reimbursement standards for Astellas Korea’s Xospata, a drug for patients with relapsed or refractory acute myeloid leukemia (AML) with
- Company
- Reimb of COVID-19 drugs necessary with eased crisis level
- by Eo, Yun-Ho Nov 22, 2023 05:30am
- Whether COVID-19 treatments will be able to be listed for reimbursement before Korea's COVID-19 containment measures are lifted remains under attention. Two COVID-19 treatments, Gilead Science Korea’s ‘Veklury (remdesivir)’ and Pfizer Korea’s ‘Paxlovid (nirmatrelvir+ritonavir),’ are currently under review by the Health Insurance Rev
- Company
- Mitsubishi’s Lou Gehrig's disease drug Radicut's sale soars
- by Nho, Byung Chul Nov 21, 2023 05:48am
- The latecomer injection formulations are taking over the Lou Gehrig's disease treatment market that had been occupied by injectables in the past. According to the industry’s pharmaceutical distribution performance data, Mitsubishi Tanabe Pharma Korea's Radicut Inj (edaravone) has occupied 39% of the market share in the related treatme
- Company
- IL inhibitor reimb as 1st-line Tx for ankylosing spondylitis
- by Eo, Yun-Ho Nov 21, 2023 05:48am
- Interleukin inhibitors may soon be available as first-line treatment for ankylosing spondylitis in Korea. On the 20th, the Ministry of Health and Welfare announced an amendment notice that contains a plan to expand insurance reimbursement for the 2 IL-17A inhibitors approved in Korea - Novartis Korea's 'Cosentyx (secukinumab)' and Lilly K
- Company
- Yuhan Leclaza clinical phase 3 cost exceeds 100 billion
- by Chon, Seung-Hyun Nov 20, 2023 05:50am
- The development cost invested by Yuhan's new anti-cancer drug Leclaza in the Phase 3 clinical trial has exceeded 100 billion won. Three years after the start of the clinical trial, the cost of development is also increasing. Yuhan was approved as a primary treatment based on the efficacy and safety of Leclaza confirmed in the clinical trial,
